Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Bitdeer Technologies Group (BTDR) vs Mesoblast Limited (MESO) Price & Performance

Bitdeer Technologies GroupTrade
Mesoblast LimitedTrade

Price performance (Past 24H)

Key statistics

Bitdeer Technologies Group vs Mesoblast Limited — how do they compare? Bitdeer Technologies Group trades at $8.85 (market cap $2.12B), while Mesoblast Limited trades at $16.68 (market cap $2.16B). The key difference: Bitdeer Technologies Group and Mesoblast Limited are close in size by market cap, and Mesoblast Limited is trading nearer its 52-week high, Bitdeer Technologies Group nearer its low. Which is the better fit depends on your goals.

BTDRMESO
Market Cap
$2.12B$2.16B
Sector
TechnologyTechnology
52-Week High
$25.90$20.96
52-Week Low
$7.28$12.88
Enterprise Value
$3.88B$2.17B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Bitdeer Technologies Group

BTDR trades at $10.88, up 3.42% today, but remains under bearish technical pressure with recent earnings misses. Revenue grew to $620.25M in 2025, yet net income margin turned negative at -26.96% in 2026. The company secured a significant $4.7B AI data center deal, expanding beyond Bitcoin mining. Analyst consensus is strongly bullish with an 81.82% buy rating and a $22.71 price target, suggesting over 100% upside from current levels.

Outlook: High growth potential from AI infrastructure expansion contrasts with profitability challenges and negative cash flow. Risks include execution on new contracts and persistent earnings volatility. The stock offers speculative upside if operational improvements align with analyst optimism.

Mesoblast Limited

MESO trades at $15.94, up 2.05% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Ryoncil net revenues of $36 million for Q2 2026 (GlobeNewsWire, July 29, 2026), showing commercial traction, yet fundamentals reveal a net loss of -$102.14 million in 2025 with a negative net margin. Valuation metrics include a P/S of 30.52 and P/B of 3.76, indicating high growth expectations.

Outlook hinges on Ryoncil's expansion and pipeline progress, but risks include sustained losses and regulatory hurdles. Analysts are cautiously optimistic with 45% buy ratings, yet the stock faces volatility from earnings misses and high cash burn.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Bitdeer Technologies Group

Bitdeer is a world-leading technology company for blockchain and high-performance computing. It provides comprehensive digital asset mining solutions, including cloud mining, hosting, and data center management.

Read more on BTDR

About Mesoblast Limited

Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.

Read more on MESO